MX2023006374A - Formulaciones. - Google Patents

Formulaciones.

Info

Publication number
MX2023006374A
MX2023006374A MX2023006374A MX2023006374A MX2023006374A MX 2023006374 A MX2023006374 A MX 2023006374A MX 2023006374 A MX2023006374 A MX 2023006374A MX 2023006374 A MX2023006374 A MX 2023006374A MX 2023006374 A MX2023006374 A MX 2023006374A
Authority
MX
Mexico
Prior art keywords
filaments
hot melt
melt extrusion
devices
diseases
Prior art date
Application number
MX2023006374A
Other languages
English (en)
Inventor
Sarah Marquette
Jonathan Eleuthère Maurice Goole
Emeric Carlier
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2023006374A publication Critical patent/MX2023006374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona al campo de las composiciones farmacéuticas que comprenden proteínas como agentes terapéuticos. Más particularmente, se dirige a los filamentos que contienen anticuerpo producidos de extrusión de masa fundida en caliente, dispositivos de suministro de fármaco implantables hechos de estos filamentos y a métodos para producir los filamentos y dispositivos. Los filamentos que contienen el anticuerpo producido por extrusión de masa fundida caliente y los dispositivos obtenidos a partir de los filamentos de conformidad con la invención permiten el suministro del anticuerpo sobre un cierto periodo de tiempo.
MX2023006374A 2020-12-01 2021-11-29 Formulaciones. MX2023006374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2018889.2A GB202018889D0 (en) 2020-12-01 2020-12-01 Formulations
PCT/EP2021/083401 WO2022117512A1 (en) 2020-12-01 2021-11-29 Formulations

Publications (1)

Publication Number Publication Date
MX2023006374A true MX2023006374A (es) 2023-06-28

Family

ID=74099976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006374A MX2023006374A (es) 2020-12-01 2021-11-29 Formulaciones.

Country Status (11)

Country Link
US (1) US20240000719A1 (es)
EP (1) EP4255396A1 (es)
JP (1) JP2023551066A (es)
KR (1) KR20230115992A (es)
CN (1) CN116490168A (es)
AU (1) AU2021393729A1 (es)
CA (1) CA3201478A1 (es)
GB (1) GB202018889D0 (es)
IL (1) IL303232A (es)
MX (1) MX2023006374A (es)
WO (1) WO2022117512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202103785D0 (en) * 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
RU2676102C2 (ru) * 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201601865D0 (en) * 2016-02-02 2016-03-16 Ucl Business Plc Oral dosage products and processes

Also Published As

Publication number Publication date
GB202018889D0 (en) 2021-01-13
WO2022117512A1 (en) 2022-06-09
CA3201478A1 (en) 2022-06-09
CN116490168A (zh) 2023-07-25
KR20230115992A (ko) 2023-08-03
EP4255396A1 (en) 2023-10-11
JP2023551066A (ja) 2023-12-06
US20240000719A1 (en) 2024-01-04
AU2021393729A1 (en) 2023-07-06
IL303232A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
JP2005538099A5 (es)
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
RU2014138036A (ru) Пероральные фармацевтические композиции дабигатрана этексилата
PH12020550341A1 (en) Niraparib formulations
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
JP2015501830A5 (es)
WO2018150326A1 (en) Combination treatment for cancer
JP2017160178A5 (es)
TWI264311B (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
PH12021551232A1 (en) Haloallylamine compounds and application thereof
MX2023006374A (es) Formulaciones.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2021007322A (es) Formulaciones farmaceuticas que contienen relacorilant, un compuesto de azadecalina fusionado con heteroaril-cetona.
MX2023008671A (es) Composicion farmaceutica.
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202192180A1 (ru) Ингибитор киназы atr bay 1895344 для применения для лечения гиперпролиферативного заболевания
MX2021009082A (es) Compuestos quimicos.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.